# Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

> **NCT07686263** · PHASE3 · RECRUITING · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 472 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline/Trospium Chloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07686263
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-20
- **Primary completion:** 2029-03-03
- **Final completion:** 2029-03-03
- **Target enrollment:** 472 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686263, "Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*